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A B S T R A C T  
A consensus was developing based on immunity, children and aged are more susceptible to SARS-
CoV-2 infection than healthy young adults. Along this line of concept neonates are most vulnerable 
to COVID-19; however, and in fact, it is not the case. Neonates born to COVID-19 mothers are less 
or not affected. Among the new-born 60-80% develop hyperbilirubinemia, known as neonatal 
jaundice. Bilirubin in plasma up to certain level is beneficial for many reasons, including free radical 
scavenging. In view of this, I hypothesize that hyperbilirubinemia may protect new-born from 
COVID-19, and sufficient care necessary for antiviral-induced liver damage during the treatment of 
SARS-CoV-2 infection. 
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1 Introduction 
Through this communication, I would like to draw kind attention of clinical researchers, pathologists and 
basic scientists about an important metabolic product, bilirubin in circulation, and suggest keeping record 
of total bilirubin of all hospitalized COVID-19 patients along with other laboratory tests, including C-
reactive protein, alanine aminotransferase and aspartate aminotransferase. Bilirubin, the end product of 
hememetabolism is the cytotoxic as well as neurotoxic pigment of jaundice,and 60 percent of full-term 
babies and 80 percent of those born prematurely suffer from itand manifested by yellowish coloration of 
body, including eyes (1-8). Normal blood total bilirubin level ranges from1.71 to 20.5 µmol/L (9). 
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)infection put the human society in a 
devastating disorder, as the COVID-19 public-health emergency is (10-12). It is the prime time to find 
out any minute reason for remedy against the outbreak. As stated elsewhere in numbers of reports about 
hospitalized adult patients with severe COVID-19,use of Remdesivir(pro-analogue of adenosine 
triphosphate) accelerate clinical improvement (10). Although there are major side effects of multiple 
antibiotics, triple antiviral therapy with interferon beta-1b, lopinavir–ritonavir, and ribavirin were safe and 
superior to lopinavir–ritonavir alone(11).Convalescent plasma therapy also exhibited some promise 
(12).In view of this, and to focus a vision into the pathophysiological and laboratory data for better 
treatment options of COVID-19 is discussed in this article. 
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2 Neonates and COVID-19: Chances of vertical transmission and infection after birth 
Theimmunity profiles of the neonates and infants are not developed as compare to young adults (13-15). 
However, in comparison to the adults, both young and aged, new-borns are far less susceptible to SARS-
CoV-2.Based on the data sources a retrospective studies with nucleic acid (qRT-PCR)-confirmed four 
neonatal COVID-19 infections identified among the 81 026 confirmed cases in China as of March 13, 
2020 (16). Another example in consistent with previous studies, is the clinical symptoms of 33 neonates 
studied by other group(17).Only three neonates were with symptomatic COVID-19 risk; however, 
outcomes were favourable.The most severe ill neonate might havesuffered from prematurity, asphyxia, 
and sepsis, rather than SARS-CoV-2 infection(17).An official report on multi-system inflammatory 
syndrome potentially linked with COVID-19 was issued on May 4 by the New York City health 
department. It stated that 15 children ages between 2 and 15 years were hospitalized and diagnosed with 
clinical symptoms as like as toxic shock syndrome or Kawasaki disease(18). Similar illness pattern also 
reported from Europe (19).  
3 SARS-CoV-2 Genome structure and replication mechanism 
As has been understood so far, a brief look at the molecular, biochemical and replication mechanism of 
the virus would help to better understand this article. SARS-CoV-2 corona virus genome is a 
single‐stranded positive‐sense RNA (+ssRNA) of ~30 kb in length with 5′‐cap structure and 
3′‐poly‐A tail (20). The genomic RNA serves as the template having no less than 8 open reading frames 
(ORFs). It directly translates polyproteins 1a/1ab (pp1a/pp1ab), which is cleaved subsequently to several 
(~16) non-structuralproteins (NSP). Main protease cleavage products help to organise the replication 
machinery and RNA virus replication is predominantly executed by its own enzyme, RNA dependent 
RNA polymerase (RDRP). A crystal structure study with nsp12 of SARS-CoV deciphered thatnsp12 in 
association with nsp7 and nsp8 serves as the polymerase RDRP (21); however, needs primer (22).In 
general, RNA viruses RDRP lacks proof reading function; hence, their mutation rate is very high. SARS-
CoV-2 has an RDRP-independent proofreading activity, which might be a key factor that this virus has 
lower mutation rate and bigger genome (>26 kb) compared to other RNA viruses(23-27). A project 
analysed 220 SARS-CoV-2 genomic sequences and detected aneffective mutation in RDRP differing in 
amino acid composition from Italian cohorts (28), utilizing a reference sequence of SARS-CoV-2 
established by Wang et al. (29). 
4 Mechanism of SARS-CoV-2 entry into cell 
Similar to SARS-CoV, SARS-CoV-2 enters to the host cell utilizing its spike protein (S) through protein-
protein interactionswith host cell receptor angiotensin-converting enzyme 2 (ACE2), cellular serine 
protease TMPRSS2 in this event acts for spike protein priming (30, 31).Corona virus S protein contains 
two sub-domains; surface unit S1 andtransmembrane unit S2. S1 binds to a cellular receptor ACE2and S2 
facilitates fusion of the viral membrane with a cellular membrane (30, 31). Membrane fusion depends on 
S protein cleavage by host cell proteasesTMPRSS2 at the S1/S2 junction and the S2′ site, and the process 
known S protein activation. The S1/S2 junction is composed of multiple arginine residues in SARS-CoV-
2 and other human coronaviruses can form a loop structure, which is absentin SARS-CoV and other 
corona viruses (30-33).A recent report clarified the role of the loop structure (34); a cellular protease furin 
is responsible to cleave the spike protein at the S1/S2 junction. The cleavage by furin is essential for S-
protein-mediated cell-cell fusion and entry into human lung cells and pharmacological inhibition of furin 
are well known (34, 35). 
Samir Kumar Patra. AIJR Preprints, 72, version 1, 2020
Page 3 of 6 
 
AIJR Preprints 
Available online at preprints.aijr.org 
5 Excess plasma bilirubin helps neonatal lives in many ways 
Now, the question is; why new-borns are less susceptible to SARS-CoV-2? If we consider equal 
probability of infection from the mother to the offspring and mother to others; it appear in my mind that 
either there is lack of entry receptorACE2 (36) andcellular serine protease TMPRSS2 for spike protein 
priming;or after the entry the virus face the challenge of gradual increase of endogenous metabolites, 
including bilirubin during first week of neonatal lives. Enhanced bilirubin levelcause neonatal jaundice, 
which is manifested by yellow eyes. This is because bilirubin is not water soluble and, in the circulation, it 
is bound to serum albumin and transported to liver for conjugation with glucuronic acid, thus become 
water soluble and eventually excreted through urine (2, 3, 7, 37-44). The new-borns don’t have competent 
enzyme system functional during birth and the bilirubin UDP-glucuronosyltransferase synthesis in 
respective new-born liver when takes time for days, bilirubin accumulates.It is well documented by 
experimental and pathophysiological measures that infants with oxygen radical associated diseases such as 
intraventricular haemorrhage, retinopathy, and necrotizing enterocolitis had lower levels of serum 
bilirubin compared to infants without such diseases. Numbers of scientific and clinical 
reportsdemonstratedplasma bilirubin as antioxidant and jaundiced new-born generally possess higher 
superoxide dismutase, catalase, and glutathione peroxidase levels(1-5, 39-42) 
6 Discussion and conclusion 
Following phototherapy, jaundiced infants exhibit higherlevels of oxidants. Neonates with severe 
retinopathy of prematurity, grade III necrotizing enterocolitis, grade III intraventricular haemorrhage, 
severe fungal infection, and sepsis were traced with significantly lower plasma bilirubin in comparison to 
infants with high bilirubin and mild or no disease reviewed in ref. (1, 38, 42, 44).It is clearly demonstrated 
in series of clinical tests that hyperbilirubinemia increases the antioxidant capacity in blood. Consequently, 
it leads to lower oxidative stress and better outcome in free radical–associated diseases. Serum total 
bilirubin levels were inversely correlated with the prevalence of metabolic syndromes; non-alcoholic 
steatohepatitis, blood pressure and the body mass index score.Medical records of human infants suggest 
that; who experienced neonatal hyperbilirubinemia had a lower incidence of asthma in later life(1, 42, 44).  
Unfortunately, there are not enough records of bilirubin tests with neonates born from COVID-19 
diseased mother; however, diverse reports are there. A study of single patient implicated the possibility of 
vertical transmission(45), while another study with nine patients demonstrated that there is no possibility 
of intrauterine vertical transmission of COVID-19(46). There are reports that bilirubin level enhanced in 
adult COVID-19 patients by liver injury following treatments with various antivirals (11, 12, 47-50). 
Interestingly,Hung et al. in their triple combination, including interferon beta-1b, lopinavir-ritonavir and 
ribavirin therapy found no enhancement of blood bilirubin; measured value ~8.0 µmol/L(11). Duan et al. 
reported that application of convalescent plasma improved health conditions without any significant 
change of total bilirubin before and after treatment; estimated value ~13.0 µmol/L(12, see also 51). 
From the large volume of clinical and laboratory data it is clear, hyperbilirubinemia is beneficial to new-
born for many reasons (1-3, 6, 9, 37-44). Whether bilirubin helps young adults fighting COVID-19 we 
have to record dataprecautiously, and to confirm that bilirubin helps neonates fighting SARS-CoV-2 
infection, we have to rely upon animal model experiments and testing the inhibition potential of bilirubin 
against numbers of enzymes, including RDRP, main protease, ACE2,TMPRSS2 and furin. 
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